Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2013-12-04 |
Rodos BioTarget (Germany) |
undisclosed |
grant |
Federal Ministry of Economics and Technology (Germany) |
Infectious diseases |
Grant |
2013-12-02 |
Telormedix (Switzerland) |
CHF 6 million (€ 4.87 million) |
series B financing round |
Aravis Venture (Switzerland), Proquest Investments (USA) |
Cancer - Oncology - Inflammatory diseases |
Series B financing round |
2013-11-27 |
Bioaxial (France) |
€ 1.9 million |
equity investment |
CEA Investissement (France), Inserm Transfert Initiative (France), |
Medical devices |
Fundraising |
2013-11-26 |
Bioxodes (Belgium) |
€ 2.6 million |
seed financing round |
business angels, European Regional Development Fund (ERDF), Walloon Region via the Retech program for Research and Technology (Belgium) |
|
Series A financing round |
2013-11-25 |
Prosensa (The Netherlands) Newcastle University (UK) |
€ 6 million |
grant |
European Commission’s Seventh Framework Program (FP7) |
Rare diseases - Neuromuscular diseases |
Grant |
2013-11-21 |
Eloxx Pharmaceuticals (Israel) |
|
seed financing |
Pontifax (Israel), Roche (Switzerland) |
Rare diseases - Genetic diseases |
Fundraising |
2013-11-20 |
Innate Pharma (France) |
€ 20.3 million |
capital increase |
US-based specialist institutional investors including QVT Financial, Redmile Groupe and Orbimed |
Cancer - Oncology - Autoimmune diseases |
Capital increase |
2013-11-20 |
Tigenix (Belgium) |
€ 12 million |
private placement |
Gri-Cel (Spain) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
Private placement |
2013-11-20 |
Pulmocide (UK) |
£17million (€20.4 million) |
financing round |
Imperial Innovations Group (UK), SV Life Sciences (UK - USA), Fidelity Biosciences (USA), Johnson & Johnson Development Corporation (JJDC) (USA) |
Infectious diseases -Respiratory diseases |
Fundraising |
2013-11-19 |
Oxford BioMedica (UK) |
£5 million (€ 5.95 million) |
loan |
Vulpes Life Sciences Fund (Singapore) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Loan |
2013-11-18 |
Cytos Biotechnology (Switzerland) |
CHF 24.3 million (€19.7 million) |
share placement |
Abingworth (UK), venBio (USA), Aisling Capital (USA), Amgen (USA) |
Allergic diseases - Immunological diseases |
Private placement |
2013-11-18 |
Mission Therapeutics (UK) |
£ 20 million (€ 23.9 million) |
series B financing round |
Imperial Innovations (UK), Pfizer Venture Investments (USA), Sofinnova Partners (France), SR One (UK), Roche Venture Fund (Switzerland) |
Cancer - Oncology |
Series B financing round |
2013-11-18 |
Ganymed Pharmaceuticals (Germany) |
€ 45 Million |
Series E financing round |
ATS Beteiligungsverwaltung GmbH (Germany), MIG Fond (Germany), FCPB Gany GmbH (Germany) |
Cancer - Oncology |
Fundraising |
2013-11-14 |
DBV Technologies (France) |
€29,9 million |
private placement |
|
Allergic diseases - Immunological diseases |
Private placement |
2013-11-13 |
Antabio (France) |
€ 742,000 |
|
Bpifrance (France) |
Infectious diseases |
Fundraising |
2013-11-05 |
Midatech (UK) |
£10 Million (€11.9 million) |
|
Ippon Capital (Switzerland) |
Cancer - Oncology - Metabolic diseases |
Fundraising |
2013-11-05 |
Bionor Pharma (Norway) |
NOK 20.6 million (€ 2.26 million) |
capital increase |
|
Infectious diseases |
Capital increase |
2013-11-04 |
MiRacle Consortium [InteRNA Technologies (The Netherlands), VU University Medical Center (The Netherlands), Quiet Therapeutics (Israel), Octoplus, subsidiary of Dr. Reddy’s Laboratories(The Netherlands) LPT (Germany) BioSpring (Germany)] |
€ 1.2 Million |
grant |
European Commission’s Seventh Framework Program (FP7) |
Cancer - Oncology |
Grant |
2013-11-04 |
Hookipa Biotech (Austria) |
€20 million |
series B financing round |
BioMedPartners (Switzerland), Boehringer Ingelheim Venture Fund (Germany), Forbion Capital Partners (The Netherlands), Sofinnova Partners (France), Takeda Ventures (Japan) |
Cancer - Oncology - Infectious diseases |
Series B financing round |
2013-11-04 |
Edmond de Rothschild Investment Partners (France) |
€192 million |
|
Edmond de Rothschild Group (France), BPI France (France), insurance companies, retirement funds, public pension funds, social institution, other institutional investors |
|
Establishment of a new subsidiary in the EU |